⇚ Regimen Single Agent PEMAZYRE® - for Cholangiocarcinoma Medical Name Single Agent PEMAZYRE® (Pemigatinib) for unresectable locally advanced or metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) fusion or other rearrangement. Cycles Given N/A Delivery Phases N/A Special Instructions PEMAZYRE® is given orally once daily with or without food. Monitor patients closely for vomiting, diarrhea, hyper or hypophosphatemia. Treatment continued until disease progression or unacceptable toxicity. References Abou-Alfa GK, et al. Lancet Oncol. 2020 - VIEW External References http://pubmed.ncbi.nlm.nih.gov/32203698/ - VIEW Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration PEMAZYRE® (Pemigatinib) PO QD 13.5 mg D1 thru D14 q21 N/A N/A N/A